<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660332</url>
  </required_header>
  <id_info>
    <org_study_id>H-16036538</org_study_id>
    <nct_id>NCT03660332</nct_id>
  </id_info>
  <brief_title>The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally</brief_title>
  <acronym>DUIL-6</acronym>
  <official_title>The Effect of an Acute Increase in Plasma IL-6 on Glucose Tolerance When a Meal is Administered Intraduodenally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate and clarify whether the effect of IL-6 on glucose&#xD;
      tolerance and insulin secretion are secondary to the changes in gastric emptying.&#xD;
&#xD;
      The literature provides no information regarding a role for interleukin-6 (IL-6) in the&#xD;
      regulation of beta cell function (glucose or meal-stimulated insulin secretion) in humans.&#xD;
      Previous studies infusing IL-6 into humans have primarily focused on insulin action and the&#xD;
      effects on peripheral insulin sensitivity whereas a potential effect on insulin secretion has&#xD;
      been neglected.&#xD;
&#xD;
      We have demonstrated that an acute increase in IL-6, obtained by a single bolus of IL-6,&#xD;
      potentiated glucose-induced insulin secretion in a glucagon-like peptide-1 (GLP-1) dependent&#xD;
      manner in mice1. In mice, IL-6 enhanced insulin secretion in a dose- and glucose-dependent&#xD;
      manner, along with increasing concentrations of GLP-1. Interleukin-6 had no effect on insulin&#xD;
      secretion in GLP-1 receptor knock-out mice or in mice treated with the GLP-1 receptor&#xD;
      antagonist. Thus, in mice, GLP-1 has proven an essential mediator of IL-6 actions on beta&#xD;
      cell function.&#xD;
&#xD;
      Importantly, a single bolus of IL-6 also significantly increased glucose-stimulated insulin&#xD;
      secretion in several mouse models of obesity and diabetes (diet-induced obesity, the ob/ob&#xD;
      and the db/db mouse).&#xD;
&#xD;
      Own data show that an infusion of IL-6 causes a significant delay in the rate of gastric&#xD;
      emptying (GE) after a mixed meal in healthy young men. Data showed that this delay in GE is&#xD;
      associated with much improved glucose tolerance and insulin secretion (unpublished data).&#xD;
&#xD;
      In the present study we wish to investigate whether the beneficial effects of IL-6 on&#xD;
      postprandial glucose tolerance and insulin secretion are dependent on a delay in gastric&#xD;
      emptying. We will bypass the ventricle and infuse a mixed meal directly into the duodenum of&#xD;
      healthy young men.&#xD;
&#xD;
      This study has the potential to show that the known effect of IL-6 on postprandial glucose&#xD;
      tolerance is dependent on a delayed GE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">April 1, 2017</completion_date>
  <primary_completion_date type="Actual">April 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The paracetamol uptake</measure>
    <time_frame>0-14 days</time_frame>
    <description>paracetamol blood levels (mmol/l) on both study days. The paracetamol absorbance will be compared between the 2 study days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1 secretion</measure>
    <time_frame>0-14 days</time_frame>
    <description>Active GLP-1 blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>0-14 days</time_frame>
    <description>Glucagon blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>0-14</time_frame>
    <description>Insulin blood levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>0-14</time_frame>
    <description>Plasma glucose levels on both study days. The levels on the 2 study days will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Postprandial Glucose Homeostasis</condition>
  <arm_group>
    <arm_group_label>IL-6 infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy young men will receive IL-6 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy young men will receive saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Infusion of a liquid meal intraduodenally</intervention_name>
    <description>Infusion of IL-6/NaCL before a liquid meal intraduodenally</description>
    <arm_group_label>IL-6 infusion</arm_group_label>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years and ≤ 35 years&#xD;
&#xD;
          -  Healthy (based on screening)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  BMI &lt; 18 and &gt; 25 kg/m2&#xD;
&#xD;
          -  Evidence of severe thyroid, liver, lung, heart or kidney disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente K Pedersen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>CFAS, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Louise Lang Lehrskov</investigator_full_name>
    <investigator_title>MD, PhD student</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

